Lumenis Ltd., a global leader in the field of minimally-invasive clinical solutions for the Surgical, Ophthalmology and Aesthetic markets, and expert in innovative energy-based technologies, including Laser, Intense Pulsed Light (IPL) and Radio-Frequency (RF), recently announced plans to launch the Lumenis Pulse™ 100H and Lumenis Pulse™ 50H during the ongoing 33rd World Congress of Endourology, which began October 1 and will run through to October 4 in London.
The Lumenis Pulse 100H follows its predecessor, the VersaPulse® PowerSuite™ 100 Watt system, and is a dynamic laser system that can treat a wide range of urologic conditions, including benign prostatic hyperplasia (BPH), stones, tumors, and structures. It can even be used in other specialties, such as general surgery, ENT, gynecology and pulmonary surgery. The Pulse 100H enables holmium laser enucleation of the prostate (HoLEP), which is the gold standard for treating BPH, and stone dusting™.
The new and improved Lumenis system boasts an extensive combination of laser parameters, offering over 70 types of procedures, along with a groundbreaking pulse reshape feature for enhanced patient safety. Other features include dual pedals for easier use, a hands-free ready and standby mode to help minimize the procedure’s cost, and a high-energy level for every pulse delivered, capable of reaching up to 3.5J with a repitition rate of up to 50Hz.
“The new Pulse 50H system provides all features to perform modern intra corporeal Holmium laser lithotripsy including a wide range of energy levels and frequencies,” said Professor Rassweiler, M.D., Ph.D., Klinikum SLK, Heilbronn-Germany.
“With our commitment to the Endourological Society, we are proud to present two new innovative systems, the Pulse 100H and 50H, to meet the developing, dynamic market need in the field of minimally invasive urological surgery,” said Tzipi Ozer-Armon, CEO of Lumenis. “The additions to the Pulse platform series signify a key improvement to our current urological solutions for HoLEP and stone dusting and empower users to achieve more than 70 types of procedures in a range of clinical specialties.”
In a new study entitled “Hormone concentration, metabolic disorders and immunoexpression of androgen and estrogen-alpha receptors in men with benign prostatic hyperplasia and testosterone deficiency syndrome” researchers investigated the occurrence of hormonal and metabolic disorders in men with benign prostatic hyperplasia who are also affected by testosterone deficiency syndrome. The study was published in the Folia Histochemica et Cytobiologica journal.